TY - JOUR
T1 - Laboratory and clinical evaluation of tazobactam/piperacillin
AU - Yamamoto, Yoshihiro
AU - Yanagihara, Katunori
AU - Ohno, Hideaki
AU - Ogawa, Kazuhiko
AU - Ohtsubo, Takakazu
AU - Miyazaki, Yoshitsugu
AU - Higashiyama, Yasuhito
AU - Miyazaki, Haruko
AU - Mitsutake, Koutaro
AU - Hashimoto, Atsurou
AU - Tomono, Kazunori
AU - Koga, Hironobu
AU - Kohno, Shigeru
AU - Moehida, Chikako
AU - Sugawara, Kazuyuki
AU - Kaku, Mitsuo
AU - Takemura, Hiromu
AU - Sugiyama, Hidenori
AU - Taniguti, Tetuo
AU - Shimoguti, Kazunori
AU - Fukushima, Kiyoyasu
AU - Hori, Hiroyuki
AU - Masuyama, Taiji
AU - Ohtsubo, Takayuki
AU - Fujita, Kiyo
AU - Ohe, Toshiyuki
AU - Okuno, Kazuhiro
PY - 1994
Y1 - 1994
N2 - A newly developed antimicrobial agent, tazobactam/piperacillin (TAZ/PIPC), was evaluated in vitro and in vitro. The results were as follows: 1) Antimicrobial activity: Minimal inhibitory concentrations (MICs) against 515 clinical isolates of 16 different species were determined and compared with 3 other drugs, piperacillin (PIPC), clavulanic acid/ticarcillin (CVA/TIPC), and sulbactam/cefoperazine (SBT/CPZ). TAZ/PIPC showed excellent antimicrobial activity against gram-positive and-negative bacteria. The MICs of TAZ/PIPC were superior to those of PIPC. 2) TAZ concentrations in serum and sputum: A patient with bronchiectasis was given 0.25 g/1.0 g of TAZ/PIPC intravenously and its concentration in serum was measured with time. The peak concentration in serum was observed immediately after the infusion, and reached 5.31 μg/ml. The peak sputum level of 0.34 μg/ml was observed 3~4 hours after infusion. This suggests that TAZ has rapid and good penetration into the sputum. 3) Clinical efficacy and adverse reaction: Twenty-three patients were treated with TAZ/PIPC. The overall efficacy rate was 95%(excellent in 5 cases, good in 14, poor in 1, and not evaluable in 3). Stomatitis and nausea were observed in one case each as adverse reactions. As abnormal laboratory findings, elevation of GOT was observed in 1 case and eosinophilia in 1. All of these were mild and improved rapidly after the completion of administration, indicating that TAZ/PIPC is a safe agent.
AB - A newly developed antimicrobial agent, tazobactam/piperacillin (TAZ/PIPC), was evaluated in vitro and in vitro. The results were as follows: 1) Antimicrobial activity: Minimal inhibitory concentrations (MICs) against 515 clinical isolates of 16 different species were determined and compared with 3 other drugs, piperacillin (PIPC), clavulanic acid/ticarcillin (CVA/TIPC), and sulbactam/cefoperazine (SBT/CPZ). TAZ/PIPC showed excellent antimicrobial activity against gram-positive and-negative bacteria. The MICs of TAZ/PIPC were superior to those of PIPC. 2) TAZ concentrations in serum and sputum: A patient with bronchiectasis was given 0.25 g/1.0 g of TAZ/PIPC intravenously and its concentration in serum was measured with time. The peak concentration in serum was observed immediately after the infusion, and reached 5.31 μg/ml. The peak sputum level of 0.34 μg/ml was observed 3~4 hours after infusion. This suggests that TAZ has rapid and good penetration into the sputum. 3) Clinical efficacy and adverse reaction: Twenty-three patients were treated with TAZ/PIPC. The overall efficacy rate was 95%(excellent in 5 cases, good in 14, poor in 1, and not evaluable in 3). Stomatitis and nausea were observed in one case each as adverse reactions. As abnormal laboratory findings, elevation of GOT was observed in 1 case and eosinophilia in 1. All of these were mild and improved rapidly after the completion of administration, indicating that TAZ/PIPC is a safe agent.
KW - tazobactam/piperacillin
UR - http://www.scopus.com/inward/record.url?scp=0028100059&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028100059&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.42.Supplement2_443
DO - 10.11250/chemotherapy1953.42.Supplement2_443
M3 - Article
AN - SCOPUS:0028100059
SN - 0009-3165
VL - 42
SP - 443
EP - 451
JO - CHEMOTHERAPY
JF - CHEMOTHERAPY
ER -
